On January 2, 2025 Star Therapeutics,a clinical stage biotechnology company discovering and developing best-in-class antibodies, reported that it will present at the 43rd annual J.P. Morgan Healthcare Conference taking place on January 13-16, 2025 in San Francisco, CA (Press release, Star Therapeutics, JAN 2, 2025, View Source [SID1234649381]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Adam Rosenthal, Ph.D., CEO and Founder of Star Therapeutics, is scheduled to present an overview of the company and its lead drug candidate, VGA039, a therapy for von Willebrand disease (VWD) and other bleeding disorders. The presentation details are below:

Date: Tuesday, January 14
Time: 9:30 a.m. PT
Location: The Westin St. Francis

About VGA039

VGA039 is a monoclonal antibody therapy with a novel mechanism of action that targets Protein S, a key component in restoring balance to the blood clotting process. VGA039 has potential to be a universal hemostatic therapy that can treat numerous bleeding disorders, with the first disease indication of von Willebrand disease (VWD). As a subcutaneously self-administered antibody therapy with a convenient dosing regimen, VGA039 has the potential to dramatically reduce treatment burden for patients.